IL286767A - Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases - Google Patents
Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseasesInfo
- Publication number
- IL286767A IL286767A IL286767A IL28676721A IL286767A IL 286767 A IL286767 A IL 286767A IL 286767 A IL286767 A IL 286767A IL 28676721 A IL28676721 A IL 28676721A IL 286767 A IL286767 A IL 286767A
- Authority
- IL
- Israel
- Prior art keywords
- neurodegenerative
- compositions
- treatment
- methods
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828995P | 2019-04-03 | 2019-04-03 | |
| US201962879794P | 2019-07-29 | 2019-07-29 | |
| US201962933632P | 2019-11-11 | 2019-11-11 | |
| PCT/US2020/026732 WO2020206363A1 (en) | 2019-04-03 | 2020-04-03 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286767A true IL286767A (en) | 2021-12-01 |
Family
ID=72666280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286767A IL286767A (en) | 2019-04-03 | 2021-09-29 | Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220162215A1 (https=) |
| EP (1) | EP3947390A4 (https=) |
| JP (1) | JP2022527025A (https=) |
| KR (1) | KR20220004068A (https=) |
| CN (1) | CN114026093A (https=) |
| AU (1) | AU2020253561A1 (https=) |
| BR (1) | BR112021019802A2 (https=) |
| CA (1) | CA3135755A1 (https=) |
| IL (1) | IL286767A (https=) |
| MX (1) | MX2021012129A (https=) |
| WO (1) | WO2020206363A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018290225A1 (en) | 2017-06-21 | 2020-01-23 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| US20250129080A1 (en) * | 2021-08-20 | 2025-04-24 | Mitokinin, Inc. | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
| WO2023023671A1 (en) * | 2021-08-20 | 2023-02-23 | Mitokinin, Inc. | Compositions and methods for treatment of neurodegenerative and mitochondrial disease |
| WO2024040266A2 (en) * | 2022-08-19 | 2024-02-22 | Mitokinin, Inc. | Disubstituted benzoimidazole and indole analogs as modulators of pink1 |
| EP4620957A1 (en) * | 2024-03-22 | 2025-09-24 | Eberhard Karls Universität Tübingen | Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof |
| CN118290348A (zh) * | 2024-03-22 | 2024-07-05 | 诚达药业股份有限公司 | 一种4-氯吡咯并嘧啶类化合物或其衍生物的合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| CN101282761A (zh) * | 2005-08-04 | 2008-10-08 | 西特里斯药业公司 | 作为sirtuin调节剂的苯并咪唑衍生物 |
| ES2412384T3 (es) * | 2006-07-18 | 2013-07-11 | Astellas Pharma Inc. | Derivado de aminoindano o sal del mismo |
| WO2014124458A1 (en) * | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
| EP2818472A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
| ES2919024T3 (es) * | 2014-02-11 | 2022-07-21 | Mitokinin Inc | Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales |
| JP2018537502A (ja) * | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018106818A1 (en) * | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| AU2018290225A1 (en) * | 2017-06-21 | 2020-01-23 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| CN115515682B (zh) * | 2020-02-21 | 2024-06-21 | 麦托吉宁公司 | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 |
-
2020
- 2020-04-03 AU AU2020253561A patent/AU2020253561A1/en not_active Abandoned
- 2020-04-03 CN CN202080040787.8A patent/CN114026093A/zh active Pending
- 2020-04-03 BR BR112021019802A patent/BR112021019802A2/pt not_active Application Discontinuation
- 2020-04-03 KR KR1020217035783A patent/KR20220004068A/ko not_active Withdrawn
- 2020-04-03 MX MX2021012129A patent/MX2021012129A/es unknown
- 2020-04-03 CA CA3135755A patent/CA3135755A1/en active Pending
- 2020-04-03 EP EP20784272.5A patent/EP3947390A4/en not_active Withdrawn
- 2020-04-03 US US17/601,372 patent/US20220162215A1/en not_active Abandoned
- 2020-04-03 WO PCT/US2020/026732 patent/WO2020206363A1/en not_active Ceased
- 2020-04-03 JP JP2021560413A patent/JP2022527025A/ja active Pending
-
2021
- 2021-09-29 IL IL286767A patent/IL286767A/en unknown
-
2025
- 2025-03-24 US US19/088,609 patent/US20250250276A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250250276A1 (en) | 2025-08-07 |
| MX2021012129A (es) | 2022-01-31 |
| KR20220004068A (ko) | 2022-01-11 |
| JP2022527025A (ja) | 2022-05-27 |
| BR112021019802A2 (pt) | 2021-12-07 |
| EP3947390A1 (en) | 2022-02-09 |
| EP3947390A4 (en) | 2022-11-30 |
| CA3135755A1 (en) | 2020-10-08 |
| CN114026093A (zh) | 2022-02-08 |
| WO2020206363A1 (en) | 2020-10-08 |
| AU2020253561A1 (en) | 2021-12-02 |
| US20220162215A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| IL286767A (en) | Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| IL260352B (en) | Methods and preparations for the treatment of neurological disease | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| SMT202500382T1 (it) | Composizioni per trattare e/o prevenire malattie da aggregazione proteica | |
| IL274588A (en) | Methods and preparations for improving lysosome function and treating neurodegenerative disease | |
| IL295681B1 (en) | Compositions and methods of use thereof for treating neurodegenerative and mitochondrial diseases | |
| GB201702603D0 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| SG11202103070VA (en) | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases | |
| EP3672583A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| IL276228A (en) | Compounds and preparations for the treatment of pain | |
| HK40067779A (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201720101D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201809836D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| HK40009011A (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |